Home / Transcripts / Rubicon Research Limited (RUBICON) · November 5, 2026

Rubicon Research Limited (RUBICON) Earnings Call Transcript

November 5, 2026

NSEI IN Health Care Pharmaceuticals earnings 42 min

Earnings Call Speaker Segments

Operator operator
#1

Ladies and gentlemen, good day, and welcome to the Rubicon Research Limited Q2 FY '27 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Tushar Manudhane from Motilal Oswal Financial Services Limited. Thank you, and over to you, sir.

Tushar Manudhane analyst
#2

Thanks, Steve. On behalf of Motilal Oswal Financial Services, I welcome you all for Q2 FY '27 Results Earnings Call of Rubicon Research Limited. From the management side, we have Mr. Parag Sancheti, Chief Executive Officer; Mr. Nitin Jajodia, Chief Financial Officer; and Mr. Sagar Oak, Senior VP, Corporate Development and Strategy. Over to you, sir, for the opening comments.

Parag Sancheti executive
#3

[indiscernible] Rubicon's quarter 2 earnings call. We'll just start with the financial highlights. I'm on Slide #5. If you look at all the parameters, revenue, EBITDA and PAT, we've had a strong performance. If you look from Q2 FY '26, our revenue was INR 412 crores. In Q2 FY '27, our revenue is INR 577 crores. EBITDA was INR 95 crores versus in the current quarter, INR 146 crores. PAT has increased from INR 54 crores to INR 90 crores. The FY '27 numbers reflect the Arinna consolidation. So if you look at the footnote, the revenue of INR 19.4 crores is included, but contribution to EBITDA is not material in both the quarters. We can move to the next slide. I'll request Nitin to take you through the summary income statement.

Nitin Jajodia executive
#4

Thanks, Parag. Good evening, everyone, and I'm on the Slide #6. So in the quarter 2, our revenue from operation was INR 576 crores versus INR 412 crores in the previous year, up by 40%. And in the quarter 1, '27, our revenue was INR 534 crores. Operating pre-R&D EBITDA was INR 206 crores versus INR 141 crores in the previous year, and that translates into a pre-R&D EBITDA margin of 35.8% in this quarter versus 34.1% in the previous year same quarter. Our R&D expense for the quarter was at INR 62 crores, translating into 10.8% R&D expense, which is in line with the previous year same quarter and the Q1 of FY '27. Our operating EBITDA was INR 144 crores versus INR 94 crores in the previous year, a healthy growth of almost 53%. In the quarter 1, our EBITDA was INR 129 crores, so even sequentially a strong growth. Including other income, our EBITDA was INR 146 crores in this quarter versus INR 95 crores in the previous year, again, a healthy growth of 54%. Our PAT for Q2 was INR 90 crores versus INR 54 crores in previous year and INR 85 crores in the previous quarter. In the previous quarter, quarter 1, our PAT of INR 85 crores also included a onetime insurance claim of INR 3.6 crores. So considering that, the PAT growth versus previous quarter is very healthy. EPS for the quarter was INR 5.41 versus INR 3.47 in the previous quarter. On a half yearly basis, our H1 revenue was INR 1,111 crores, again, a healthy growth rate of 45%. Our EBITDA pre-R&D was INR 394 crores, translating into a 35.4% pre-R&D EBITDA. Our operating EBITDA for first half was INR 273 crores, a healthy growth of 57.5% versus the H1 previous year. And our PAT for first half was INR 175 crores, again, a healthy growth of 80% versus the H1 of previous year. So just to summarize, in Q2, we saw a strong sequential as well as Y-o-Y growth, both on top line as well as bottom line. Now moving on to the Slide 7 on balance sheet. In balance sheet, movement in net debt, net of cash as well as fixed assets versus March was primarily driven by our acquisition of Arinna Life Science, our acquisition of New Jersey-based manufacturing facility as well as CapEx. So on New Jersey facility, our CapEx or the fixed asset base grew by INR 85 crores, whereas the cash payout was INR 29 crores. We had INR 55 crores worth of noncash item in the form of right of use. Our working capital as on 30th September was 117 days. The improvement in net working capital to 117 days versus 126 days was primarily driven by quarterly fluctuation, and this net working capital should normalize in the range of 125 days to 130 days. Our ROACE as on 30th of September was healthy 36%, in line with 36% in March '26. On ROACE, I would like to highlight that, out of our total capital employed, almost INR 400 crores, which is slightly more than 25% of the capital employed is towards asset which are either pre-revenue or yet to significantly or materially contribute to the revenue and the returns. So this includes our Pithampur facility, which should get operationalized soon, includes our upcoming facility in Chhatrapati Sambhajinagar or Aurangabad and our New Jersey-based facility. So these are three new manufacturing facility. And it also includes Arinna Life Sciences. So considering that, a very healthy ROACE. Now moving on to Slide 8 on the summary cash flow statement. So for the quarter, we had a healthy net cash flow from operation of INR 99 crores. And -- sorry, it is for the first half, not for the quarter. And in the first half, our cash flow in investing activity was INR 172 crores, again, primarily driven by acquisition of Arinna Life Science, our New Jersey manufacturing facility acquisition and CapEx. And again, as I mentioned earlier, the cash component in the New Jersey facility was INR 29 crores and INR 55 crores was noncash right of use. Now moving on to Slide 9. So the purpose of putting this slide was to showcase that how our R&D engine, our execution engine and our compliance engine is firing strongly. And that is getting reflected in this slide, where since listing, if you see, we've had a strong and consistent quarterly track record. So I'll not go through each and every number, but I would like to call out or highlight our EBITDA number. So if you look at -- our EBITDA has more than doubled in the last few quarters from INR 72.6 crores to INR INR 146.4 crores. So it has grown in a strong and consistent manner in the last few quarters. So with this, I'll hand over to Parag.

Parag Sancheti executive
#5

Thanks, Nitin. So just taking you broadly through the -- sorry, I'm on Slide #10, Q2 performance summary. So just taking you through some of the key highlights. So we've experienced 40% revenue growth and the revenue growth is pretty much well balanced across products. If you just see the top 5, top 10, we have put the numbers across 4 sequential quarters, and they all range bound, again, depicting a well-rounded growth across products. Pricing continues to remain stable, driven by our focus on Specialty or Differentiated products. Coming to the revenue last quarter, if you remember, we had discussed about that we have taken certain tactical measures that led to a pause in our sequential USD revenue growth. And we had guided that the growth will be back in Q2. In that light, I'm very happy to share that this quarter, our sequential USD revenue growth is 5%, and we continue to see strong visibility in the coming quarters. Coming to operating EBITDA, which is at 25%, which is up over our Q1 number. If you see again here, you see our guidance history on operating EBITDA. If you remember, we last quarter said it will be about 23% plus, which is over our 22% to 23% said earlier. We are happy to report that now we are guiding it to 24% plus for the full year. So just wanted to emphasize despite difficult geopolitical situation, we still have been able to deliver very strong EBITDA growth. Cash flow was strong at nearly INR 99 crores. Coming to approvals, three approvals came in Q2, and our commercialization rate is strong at 84%. I want to call out one important aspect regarding commercialization. The licensing process in India for controlled as well as other products have been revised. So now you can only apply for an export license once we get the FDA approval. So earlier, we used to be ready -- expecting the approval, we would be ready with the licenses and the manufactured product to ship out as soon as we receive an approval. But as these regulations have changed, some of these approvals will be launched in the coming quarter. The Specialty contribution to the gross profit is at 36%, again, underpinned by our Specialty products and Differentiated products. Moving to the next slide on Slide 11. I'll just request Sagar to take you through the regulatory inspection at all of the sites.

Sagar Oak executive
#6

Sure. Thanks, Parag. So this slide really encapsulates the current regulatory status at our all four manufacturing locations as well as both of our R&D sites. As a regulated market-focused business, these accreditations are obviously key enablers to our continued success. Both R&D facilities, as you can see, one was inspected. The Canada site was inspected earlier this year. We did not have any observations. EIR is in place. Likewise, for our Thane headquarters R&D center, which was inspected in March of 2025. Coming to manufacturing, one of the four facilities, which is New Jersey was inspected very recently just before our acquisition. So it was inspected by FDA in May of 2026, and the EIR for that is already in place. Our two facilities, Ambernath and Satara were actually inspected just in the previous month in October. So both of these were unannounced inspections. Ambernath was inspected in October. There were three observations with respect to systems improvement, two observations with regard to a product application, which was under review by the agency. All these observations are procedure. None of them relate to data integrity. And this is a very recent inspection. This inspection is literally days old, not even weeks old. And we are confident of working with the regulator to close this successfully and in a timely manner. Satara was inspected earlier in the month of October. We had one observation there, which is again procedural. The response for that has already been submitted to the agency and the EIR for that is awaited. Pithampur was inspected in July. There were two observations as we had informed the stock exchanges, the response was submitted in the same month as the inspection. And here again, we expect the EIR. So I think the key call out here is if you see all four of our manufacturing locations have now been inspected within the last 6 months. And I think that for us is obviously -- it's a key point because of sort of the criticality of regulatory inspections here. So with that, I'm going to move ahead to Slide 12. And Slide 12 provides a historical perspective on our R&D spends. So what we've always focused on in our previous calls as well is we've tried to provide insight on the productivity of our R&D spends. And from this quarter, we've made a slight change to how we are presenting this. So we've now presented 2 slides to give better perspective on both the history of our R&D spending and how that has shaped as well as how the productivity of that R&D spending has sort of evolved. So if you see going back to fiscal year 2021, when our spending on R&D was around INR 95 crores. In fiscal '22, that went up to nearly INR 125 crores, or INR 124 crores. And the key point here is that it was almost 40% of our revenues in that year. So it was really a breakout year in many ways for our R&D spend, our R&D programs. In these 2 years, as you can see, our spending on R&D relative to sales was significantly higher from 30% to 40% of revenues. And this really allowed us to build momentum in sort of R&D programs. We have since normalized this to a 10% to 11% of operating revenue range. It still, however, remains materially higher than peers. For the half year ended September, R&D spend was 10.8% of consolidated operating revenues. And all of our R&D expenses are charged off to the P&L. So while we almost look at them in some ways as investments, these expenses are all passing through the P&L. So from sort of the 40% spending in FY '22, now at sort of -- it's been fairly within range at 10% to 11% in relative terms. But what you would see is the absolute R&D, whether you see for FY '24, '25, '26, R&D spend per year has almost sort of doubled from FY '24 to FY '26. It was about INR 107 crores in FY '24 and nearly INR 194 crores in FY '26. For half year, it's been INR 120 crores. And I think as we move on to the next slide, we'll talk a little bit about what the guidance is for the coming -- for the full year as well as going forward. So I'm now on Slide #13. So here is where I think the previous slide spoke about our historical R&D spend. I think here, what you see is the correlation between that R&D spend to our incremental revenue growth. Now just to recap our construct of R&D productivity, we are comparing incremental revenue over a 3-year horizon. So if I start with the first set of data points on screen, fiscal year 2021 product sales of just under INR 300 crores. Going through to fiscal year 2024, where it grew to INR 839 crores, it's an incremental revenue of INR 540 crores, just about. And against this, we are looking at R&D spend incurred in 2 years preceding, so fiscal year '20 and '21 plus quarter 1 of fiscal year '22. And the rationale for that being the development spend on programs that was completed up to fiscal '21 with an additional quarter going beyond would begin to meaningfully impact in revenues over sort of a 3-year horizon. Now this ties in with what we have stated before in terms of our approach to commercialization, which is to say that we -- our preference has always been to ramp up new products in a steady way in a way that sort of allows us -- allows margins to be stable. So when we compare the impact of R&D, we are comparing it out over a 3-year horizon. So comparing fiscal '21 to '24, the INR 165 crores of R&D that we spent in the reference period gave us an R&D productivity of 3.3x to generate incremental revenue of about INR 540 crores. Now this is a rolling analysis. So as we roll this forward one cycle, we're now comparing '22 to '25. Revenues increased from INR 293 crores in fiscal '22 by INR 969 crores to reach INR 1,262 crores against reference R&D spend of INR 237.9 crores, INR 238 crores, the productivity went up to INR 4.1. And if you go forward, '23 to '26 and '24 to '27, you'll see that productivity has gone up further to 5.9%. Now '24 to '27 is deserves mention for a couple of reasons. I think you saw the outsized R&D spending that we had that we noted on Slide 12 in fiscal year '22, when we spent 40% of revenue on R&D. And I think you see the impact of that showing up in the absolute R&D spends of the '22 to '25 and '23 to '26 cycles, [indiscernible] INR 238 crores and INR 226 crores. And what that means is the -- if you look at the '24 to '27 cycle, that's actually coming off the lowest absolute R&D spend in the recent four cycles. So while our spending has increased, I think the impact of sort of a much higher spend a few years back means that as we look at R&D productivity, which has improved with time, the base for that R&D productivity in the current cycle is the lowest it has been in the last three cycles. So where we are at INR 218.7 crores. Now the productivity for '24 to '27, we've called that out on slide, the 5.8x number. Now the 5.8x number is just to clarify here, the revenue figure for FY '27 that you see bottom of slide, that is INR 2,105 crores. That is an arithmetic annualization of the first half revenue, excluding Arinna. Now as we have seen this year and in the preceding quarters that I think we walked through, growth in revenue in the remaining 2 quarters of the year will mean that this multiple also will correspondingly increase as we get through the remaining part of the year. Now as we look ahead, if we look at the next two cycles, fiscal '28 over fiscal '25 and fiscal '29 over fiscal '26, what you'll see is that the R&D spend for these reference period is materially higher than it is in the current cycle. And I'd just like to call out here that this R&D spend of INR 275 crores and INR 384 crores has already been completed. So if you see '25 versus '28, the reference R&D periods for that are '24, '25 and Q1 '26, which is complete as of last year. And if you see in '26 versus '29, that's the R&D spend of '25, '26 and Q1 of '27 totaling INR 384 crores, which is worth pointing out which is slightly less than double of what it is in the current cycle, and that spend has been completed also. Now coming to guidance for the current spending period, which is '26, '27 and Q1 '28. We guided to an R&D spend of INR 500 crores. So if we look at fiscal year '30 versus fiscal year '27, on sort of the fiscal year '27 revenue base, we would expect INR 500 crores of incremental R&D at the productivity rate of that R&D to drive incremental revenues to FY '30. Now of the INR 500 crores of R&D, we are well on track to achieve that guidance. We have already completed a total spend of INR 313 crores over 6 quarters, and we have good visibility towards completing the remaining INR 500 crores -- to get to the INR 500 crores number over the remaining 3 quarters. So essentially, current cycle leading up to FY '27, in many ways, if you were to treat this, if you were to look at this as sort of an engine, I mean, it has probably the least coal in the fire. And going forward, I think the next two cycles where we have already completed materially higher R&D spend. So in many ways, I think we are now building up steam for that uptick that we've pointed out here. So based on this, I think we've tried to represent this a little bit differently just to bring out the various aspects of this. So I hope it's easy to appreciate the visibility on revenue growth for '29, '30 and beyond is pretty strong for us. With that, I'll hand it back to Parag.

Parag Sancheti executive
#7

Thanks, everyone. Thanks, Sagar. I think we are open to question and answers.

Operator operator
#8

[Operator Instructions] The first question comes from the line of Nikhil Mathur with HDFC Mutual Funds.

Nikhil Mathur analyst
#9

I mean great set again. So many congrats on that. The first question I have is on -- I just wanted to understand that when you incur R&D over the period that you have talked about, do you have any metrics to talk about what percentage of R&D doesn't contribute to revenues or what percent of R&D goes waste? I mean there might be some elements of R&D which are inefficient, right? There might be some certain cases, certain products that fail. So any thought process on what has been historical run rate of R&D that usually goes waste? And going forward, will that metric be any different?

Sagar Oak executive
#10

Nikhil, thank you for that and happy Diwali in advance to you as well. So I think our approach on R&D spending has always been -- we follow a very rigorous stage-gated approach to spending on R&D. And I think the key output of that is before we commit significant capital to any project, I think the de-risking exercise and the stress testing exercise take place before. So essentially, what ends up happening is before we commit significant capital to any particular project, I think we go past all of those de-risking hurdles or stage gates, if you will. And so the outcome of that is it allows us to keep nonproductive R&D spend down to as little as we can, which is not to say that we don't have any spend. Yes, there are some projects that get paused or stopped later in their life cycle as well. But I think if you look at our increasing trend of R&D productivity, it's sort of reflective of the fact that we've been continuously getting a little bit better at it with time. And going forward also, I think you will see this -- I mean, it's cultural for us. You will see this approach and philosophy will continue, and we will look to keep strengthening it even further as we go along.

Nikhil Mathur analyst
#11

Okay. So the current R&D to revenue ratio, which is on an uptrend, is it only because of your revenue per molecule is going up? Or is it also an element of that you have gone more efficient over the years and hence, you're able to convert more of your R&D to revenues?

Sagar Oak executive
#12

So it would be a combination. I think, Nikhil, great question. I think it will definitely be a combination of both.

Nikhil Mathur analyst
#13

Okay. And so the further uptrend that you're talking about on this metric, again, you have visibility and line of sight on the kind of products that you're launching and the realization or the opportunity per product is kind of going up. That's how one should look at it?

Sagar Oak executive
#14

So over years, I think the color of our portfolio has definitely changed. I think if you look at the years that we've laid out on Slide 13, starting with sort of -- I'll run the risk of saying relatively simpler products, immediate release tablets going back to 2021 and so on. But as you move forward and closer to '26, '27, I think you see drug device combinations, products that present sizably large individual opportunities as well. Now all of this is still within the context of there being no hero products as such. So I think Parag said earlier that if you look at our top 5, top 10 products, those have not moved outside sort of a fairly narrow band, and I think that continues. I think the approach is to be broad-based on portfolio and to keep driving both efficiencies as well as keep continue with the focused product selection approach.

Nikhil Mathur analyst
#15

Got it. Understood. I have one clarification on Slide 13. So the -- if I look at, let's say, the current year revenue buildup, which is FY '27, now you are talking about FY '24 base revenues of INR 839 crores. But when I look at audited numbers, the base year revenue is around INR 854 crores. And since there's some difference in the previous year as well. So are we missing something here? Because to project future, we might need some accuracy on what base year revenue we are looking at?

Sagar Oak executive
#16

So these -- the numbers on this slide, Nikhil, are actually product sales, which is why there is...

Nikhil Mathur analyst
#17

Revenue and service element as well in the reported?

Sagar Oak executive
#18

Yes, yes.

Nikhil Mathur analyst
#19

Okay. Got it. And finally, I have just coming to this slide...

Sagar Oak executive
#20

And Nikhil, sorry, just to call out also just for completeness sake, although the numbers are not very large, is that this is still sort of the regulated market revenue and R&D. This doesn't include the Arinna numbers. So if you're trying to reconcile the total...

Nikhil Mathur analyst
#21

And on Slide #7, the pre-revenue manufacturing site breakup that you have given, so does this mean that all of these four sites, including Arinna, they are not contributing to any revenues as of now? Or Arinna revenue is part of this particular CapEx...

Nitin Jajodia executive
#22

Yes. So the pre-revenue manufacturing sites, Nikhil, that is correct. As you know, Pithampur was...

Sagar Oak executive
#23

All the three sites are not contributing anything in revenue right now.

Nitin Jajodia executive
#24

And also from an ROACE perspective, Nikhil, the point is that all these core facilities, units are not sort of having a meaningful contribution to bottom line, okay? And if you look at out of these firstly Pithampur, CSN and New Jersey, we are incurring expenditure and the revenue is up to [indiscernible].

Parag Sancheti executive
#25

So Arinna has sort of come into the capital employed. But as we've been saying, I think that we are working on sort of getting that business on to the trajectory that we want. So it's still not contributing to the the numerator side of the return on capital. But yes, that will change going forward.

Nitin Jajodia analyst
#26

Okay. So just to understand it completely, I mean, it's 0 to very low utilization across these four line items. The pre-op expenses are being routed through the P&L and operating leverage will possibly get realized once these get commissioned and picks up?

Parag Sancheti executive
#27

It should. Actually correct, the expenditure is going through the P&L and the sites are not yet revenue [indiscernible].

Nitin Jajodia executive
#28

So basically, to summarize, basically, all these sites are adding to the basically the capital employed, okay? So these are included in the denominator and [indiscernible].

Operator operator
#29

The next question comes from the line of [indiscernible] Singh with [indiscernible] Funds.

Unknown Analyst analyst
#30

Am i audible?

Parag Sancheti executive
#31

A little soft [indiscernible], if you could speak up.

Unknown Analyst analyst
#32

Congrats on great set of numbers.

Operator operator
#33

[Operator Instructions].

Unknown Analyst analyst
#34

So congrats on the great set of numbers and happy Diwali to everyone. Sir, my question is on the 3 factories that you were talking about. So from when do you expect them to start contributing in the revenue?

Parag Sancheti executive
#35

So if I understood correctly, I think you're asking about the three facilities that we said are not contributing right now because there's no revenue generation. Is that correct?

Unknown Analyst analyst
#36

Yes, sir. So from when do you expect the revenue generation to come in place?

Sagar Oak executive
#37

Yes. So for Indore, we already said that it will be FY '28 onwards for that. CSN right now, we are not putting an exact time line to it. But -- and for New Jersey, as we had already mentioned again, it will take us before we -- revenue starts, we'll have to do filing, putting the products, then FDA inspection. So right now, we'll refrain from giving an exact date for that.

Unknown Analyst analyst
#38

Got it, sir. And secondly, sir, what would be our revenue growth on the constant currency terms?

Nitin Jajodia executive
#39

5%, I think, was the quarter sequential growth, yes 5%.

Operator operator
#40

[Operator Instructions] The next question comes from the line of Harsh Khandanila from [indiscernible].

Unknown Analyst analyst
#41

Congrats on good set of numbers. A couple of questions. First one is on the margin side. So this is the third quarter of gross and EBITDA margin expansion. So how much of this would you attribute to letting go of the lower-margin products versus specialty increasing as a percentage of gross profit or the operating leverage playing out? And did this quarter also have the impact of rationalization of low-margin products?

Parag Sancheti executive
#42

So Harsh, I think it's a combination of the factors all you mentioned, but last quarter when you mentioned that the revenue growth or sequential revenue growth was not there because of the tactical measures we've been taking. I think more or less, those measures have been completed, a few might be completed in the next 1 or 2 quarters. So that's, I think, on the revenue side. And I think -- sorry, I missed your second -- I think what was the second question?

Unknown Analyst analyst
#43

Just wanted to understand that the reason for margin expansion, like was that low-margin products or more or less specialty increasing as a percentage of GP or the leverage that is playing out?

Parag Sancheti executive
#44

No. So I think that's also based on the products -- the products gaining market share, our legacy products getting market share. So it's based and across what as I said, is well rounded. It is not only about old products or new products. It's all about the portfolio we have and the way we have designed the portfolio. So that is playing out.

Sagar Oak executive
#45

And Harsh, just to add to, as Parag mentioned earlier, it's a combination of various things. Our share of specialty in the gross margin has been healthy. As you mentioned, operating leverage. And this also factors-in that the improved gross margin and EBITDA margin is after factoring in the costs associated with the whole geopolitical situation, et cetera. So it's a combination of [indiscernible] impacted positively [indiscernible] impacted negatively.

Unknown Analyst analyst
#46

Understood. And just wanted to get an update on the Arinna integration and where do you think the Arinna margins could be, say, in the medium to long run without any guidance or anything, but where do you envisage the margins should be?

Nitin Jajodia executive
#47

So Harsh, as we mentioned that Arinna, we are in a phase wherein we are putting the growth lever in place and our focus is investing behind the growth and getting the growth back on track. And in the next phase, we are looking at beating the IPM growth. And then we'll start focusing on profitability. So we are some time away from that phase. Okay? The idea is to put Arinna back on the growth trajectory and start beating IPM growth.

Sagar Oak executive
#48

And just to add, Harsh, I think first, I think we -- instead of guiding and then not talking. And first, again, the focus, as Nitin said would be on revenue and then on margins. But we still -- these are early days for that business.

Operator operator
#49

Ladies and gentlemen, that was the last question for today. I now hand the conference over to the management for closing comments.

Parag Sancheti executive
#50

So on behalf of all of us at Rubicon, we'd like to thank all of you for attending this quarter's earnings call. We also take this opportunity to wish all of you very best for the festive season. Have a Happy Diwali, and thank you.

Tushar Manudhane analyst
#51

Thank you, sir. On behalf of Motilal Oswal Financial Services Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Rubicon Research Limited transcript - plus 261,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Rubicon Research Limited earnings transcripts and 261,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $145 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.